Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease.
The risk of lung and breast cancer is significantly increased after therapy for Hodgkin's disease (HD), but there are few data that describe the molecular profiles of these tumors. We investigated the genetic abnormalities in second primary lung (n = 19) and breast cancers (n = 19) that follow therapy for HD ("post-HD cancers") and compared these with changes observed in corresponding tumor types (57 lung and 20 breast cancers) arising in the general population ("sporadic cancers"). DNA obtained from archival tissues was examined using PCR-based analyses for loss of heterozygosity and microsatellite alterations (MAs) at several chromosomal regions, TP53 and K-ras gene mutations, and frameshift mutations at minisatellite sequences at the coding regions of several genes (TGF-betaRII, IGFIIR, BAX, hMSH6, and hMSH3). The occurrence of loss of heterozygosity at all chromosomal regions taken together and frequencies at most individual areas were similar for the post-HD and sporadic cancers for both lung and breast sites. The overall frequency of MAs in the post-HD tumors was substantially greater (lung, 2.4-fold, P = 0.004; breast, 4.2-fold, P = 0.16) than that in the respective sporadic cancers. No differences in the pattern of TP53 and K-ras mutations were detected between post-HD and sporadic cancers. No mutations were detected at the minisatellite sequences examined. MAs, which reflect widespread genomic instability, occur at greatly increased frequency in post-HD lung and breast cancers. Although the mechanisms underlying the development of increased MAs are unknown, they have been associated with immunosuppression and radiation exposure. Future research should address the role that MAs, as well as other influences, may play in the development of neoplasias that occur after therapy for HD.
Behrens
C
C
Hamon Center for Therapeutic Oncology Research University of Texas Southwestern Medical Center, Dallas 75390-8593, USA.
Travis
L B
LB
Wistuba
I I
II
Davis
S
S
Maitra
A
A
Clarke
E A
EA
Lynch
C F
CF
Glimelius
B
B
Wiklund
T
T
Tarone
R
R
Gazdar
A F
AF
D000230:Adenocarcinoma / Q000209:etiology / Q000235:genetics*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000209:etiology* / Q000235:genetics; D018270:Carcinoma, Ductal, Breast / Q000209:etiology / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000209:etiology / Q000235:genetics*; D018288:Carcinoma, Small Cell / Q000209:etiology / Q000235:genetics*; D004252:DNA Mutational Analysis; D005260:Female; D016147:Genes, Tumor Suppressor / Q000235:genetics*; D016158:Genes, p53; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D019656:Loss of Heterozygosity; D008175:Lung Neoplasms / Q000209:etiology* / Q000235:genetics; D008297:Male; D018895:Microsatellite Repeats / Q000235:genetics; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011878:Radiotherapy / Q000009:adverse effects